Erasca closed an upsized public offering, selling 25.875 million shares at $10 each to raise roughly $258.8 million before fees. The San Diego-based precision oncology company said proceeds will support its clinical-stage pipeline focused on RAS/MAPK pathway–driven cancers. The financing follows recent corporate activity in oncology capital markets and provides Erasca with runway for ongoing trials and translational work.